Pramipexole for bipolar II depression: A placebo-controlled proof of concept study

Carlos A. Zarate, Jennifer Payne, Jaskaran Singh, Jorge A. Quiroz, David A. Luckenbaugh, Kirk D. Denicoff, Dennis S. Charney, Husseini K. Manji

Research output: Contribution to journalArticle

Abstract

Background The original serotonergic and noradrenergic hypotheses do not fully account for the neurobiology of depression or mechanism of action of effective antidepressants. Research implicates a potential role of the dopaminergic system in the pathophysiology of bipolar disorder. The current study was undertaken as a proof of the concept that dopamine agonists will be effective in patients with bipolar II depression. Methods In a double-blind, placebo-controlled study, 21 patients with DSM-IV bipolar II disorder, depressive phase on therapeutic levels of lithium or valproate were randomly assigned to treatment with pramipexole (n = 10) or placebo (n = 11) for 6 weeks. Primary efficacy was assessed by the Montgomery-Asberg Depression Rating Scale. Results All subjects except for one in each group completed the study. The analysis of variance for total Montgomery-Asberg Depression Rating Scale scores showed a significant treatment effect. A therapeutic response (>50% decrease in Montgomery-Asberg Depression Rating Scale from baseline) occurred in 60% of patients taking pramipexole and 9% taking placebo (p = .02). One subject on pramipexole and two on placebo developed hypomanic symptoms. Conclusions The dopamine agonist pramipexole was found to have significant antidepressant effects in patients with bipolar II depression.

Original languageEnglish (US)
Pages (from-to)54-60
Number of pages7
JournalBiological Psychiatry
Volume56
Issue number1
DOIs
StatePublished - Jul 1 2004
Externally publishedYes

Fingerprint

Bipolar Disorder
Placebos
Depression
Dopamine Agonists
Antidepressive Agents
Neurobiology
Valproic Acid
Therapeutics
Lithium
Diagnostic and Statistical Manual of Mental Disorders
Analysis of Variance
pramipexole
Research

Keywords

  • Antidepressant
  • bipolar depression
  • dopaminergic
  • pramipexole

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Zarate, C. A., Payne, J., Singh, J., Quiroz, J. A., Luckenbaugh, D. A., Denicoff, K. D., ... Manji, H. K. (2004). Pramipexole for bipolar II depression: A placebo-controlled proof of concept study. Biological Psychiatry, 56(1), 54-60. https://doi.org/10.1016/j.biopsych.2004.03.013

Pramipexole for bipolar II depression : A placebo-controlled proof of concept study. / Zarate, Carlos A.; Payne, Jennifer; Singh, Jaskaran; Quiroz, Jorge A.; Luckenbaugh, David A.; Denicoff, Kirk D.; Charney, Dennis S.; Manji, Husseini K.

In: Biological Psychiatry, Vol. 56, No. 1, 01.07.2004, p. 54-60.

Research output: Contribution to journalArticle

Zarate, CA, Payne, J, Singh, J, Quiroz, JA, Luckenbaugh, DA, Denicoff, KD, Charney, DS & Manji, HK 2004, 'Pramipexole for bipolar II depression: A placebo-controlled proof of concept study', Biological Psychiatry, vol. 56, no. 1, pp. 54-60. https://doi.org/10.1016/j.biopsych.2004.03.013
Zarate, Carlos A. ; Payne, Jennifer ; Singh, Jaskaran ; Quiroz, Jorge A. ; Luckenbaugh, David A. ; Denicoff, Kirk D. ; Charney, Dennis S. ; Manji, Husseini K. / Pramipexole for bipolar II depression : A placebo-controlled proof of concept study. In: Biological Psychiatry. 2004 ; Vol. 56, No. 1. pp. 54-60.
@article{fd7c30bf0efe4388882e7175d6666520,
title = "Pramipexole for bipolar II depression: A placebo-controlled proof of concept study",
abstract = "Background The original serotonergic and noradrenergic hypotheses do not fully account for the neurobiology of depression or mechanism of action of effective antidepressants. Research implicates a potential role of the dopaminergic system in the pathophysiology of bipolar disorder. The current study was undertaken as a proof of the concept that dopamine agonists will be effective in patients with bipolar II depression. Methods In a double-blind, placebo-controlled study, 21 patients with DSM-IV bipolar II disorder, depressive phase on therapeutic levels of lithium or valproate were randomly assigned to treatment with pramipexole (n = 10) or placebo (n = 11) for 6 weeks. Primary efficacy was assessed by the Montgomery-Asberg Depression Rating Scale. Results All subjects except for one in each group completed the study. The analysis of variance for total Montgomery-Asberg Depression Rating Scale scores showed a significant treatment effect. A therapeutic response (>50{\%} decrease in Montgomery-Asberg Depression Rating Scale from baseline) occurred in 60{\%} of patients taking pramipexole and 9{\%} taking placebo (p = .02). One subject on pramipexole and two on placebo developed hypomanic symptoms. Conclusions The dopamine agonist pramipexole was found to have significant antidepressant effects in patients with bipolar II depression.",
keywords = "Antidepressant, bipolar depression, dopaminergic, pramipexole",
author = "Zarate, {Carlos A.} and Jennifer Payne and Jaskaran Singh and Quiroz, {Jorge A.} and Luckenbaugh, {David A.} and Denicoff, {Kirk D.} and Charney, {Dennis S.} and Manji, {Husseini K.}",
year = "2004",
month = "7",
day = "1",
doi = "10.1016/j.biopsych.2004.03.013",
language = "English (US)",
volume = "56",
pages = "54--60",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Pramipexole for bipolar II depression

T2 - A placebo-controlled proof of concept study

AU - Zarate, Carlos A.

AU - Payne, Jennifer

AU - Singh, Jaskaran

AU - Quiroz, Jorge A.

AU - Luckenbaugh, David A.

AU - Denicoff, Kirk D.

AU - Charney, Dennis S.

AU - Manji, Husseini K.

PY - 2004/7/1

Y1 - 2004/7/1

N2 - Background The original serotonergic and noradrenergic hypotheses do not fully account for the neurobiology of depression or mechanism of action of effective antidepressants. Research implicates a potential role of the dopaminergic system in the pathophysiology of bipolar disorder. The current study was undertaken as a proof of the concept that dopamine agonists will be effective in patients with bipolar II depression. Methods In a double-blind, placebo-controlled study, 21 patients with DSM-IV bipolar II disorder, depressive phase on therapeutic levels of lithium or valproate were randomly assigned to treatment with pramipexole (n = 10) or placebo (n = 11) for 6 weeks. Primary efficacy was assessed by the Montgomery-Asberg Depression Rating Scale. Results All subjects except for one in each group completed the study. The analysis of variance for total Montgomery-Asberg Depression Rating Scale scores showed a significant treatment effect. A therapeutic response (>50% decrease in Montgomery-Asberg Depression Rating Scale from baseline) occurred in 60% of patients taking pramipexole and 9% taking placebo (p = .02). One subject on pramipexole and two on placebo developed hypomanic symptoms. Conclusions The dopamine agonist pramipexole was found to have significant antidepressant effects in patients with bipolar II depression.

AB - Background The original serotonergic and noradrenergic hypotheses do not fully account for the neurobiology of depression or mechanism of action of effective antidepressants. Research implicates a potential role of the dopaminergic system in the pathophysiology of bipolar disorder. The current study was undertaken as a proof of the concept that dopamine agonists will be effective in patients with bipolar II depression. Methods In a double-blind, placebo-controlled study, 21 patients with DSM-IV bipolar II disorder, depressive phase on therapeutic levels of lithium or valproate were randomly assigned to treatment with pramipexole (n = 10) or placebo (n = 11) for 6 weeks. Primary efficacy was assessed by the Montgomery-Asberg Depression Rating Scale. Results All subjects except for one in each group completed the study. The analysis of variance for total Montgomery-Asberg Depression Rating Scale scores showed a significant treatment effect. A therapeutic response (>50% decrease in Montgomery-Asberg Depression Rating Scale from baseline) occurred in 60% of patients taking pramipexole and 9% taking placebo (p = .02). One subject on pramipexole and two on placebo developed hypomanic symptoms. Conclusions The dopamine agonist pramipexole was found to have significant antidepressant effects in patients with bipolar II depression.

KW - Antidepressant

KW - bipolar depression

KW - dopaminergic

KW - pramipexole

UR - http://www.scopus.com/inward/record.url?scp=3042561718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042561718&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2004.03.013

DO - 10.1016/j.biopsych.2004.03.013

M3 - Article

C2 - 15219473

AN - SCOPUS:3042561718

VL - 56

SP - 54

EP - 60

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 1

ER -